BackGlaukos Overview
Glaukos Corporation

Glaukos Target Price

Where could GKOS trade next? Consensus target price: $180.

Get informed when a big investor buys or sells

+ Follow

Share Price

$185.04

Average Target Price

$180.772.3% downside

13 analysts in the last 4 months

High: $215 | Low: $150

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-20BTIG$2029.2% upsideOpen
2026-07-30H.C. Wainwright$1955.4% upsideOpen
2026-07-30Stifel Nicolaus$1902.7% upsideOpen
2026-07-30Piper SandlerMatt O'Brien$1955.4% upsideOpen
2026-07-30Wells FargoLarry Biegelsen$1783.8% downsideOpen
2026-07-30NeedhamDavid Saxon$2018.6% upsideOpen
2026-07-30Truist FinancialRichard Newitter$21516.2% upsideOpen
2026-07-28UBS$15018.9% downsideOpen
2026-07-16Truist Financial$1802.7% downsideOpen
2026-07-13BTIG$16411.4% downsideOpen
2026-07-06H.C. Wainwright$1689.2% downsideOpen
2026-06-17NeedhamDavid Saxon$15018.9% downsideOpen
2026-05-21BTIGRyan Zimmerman$16212.5% downsideOpen
2026-04-30Stifel NicolausThomas Stephan$1708.1% downsideOpen
2026-04-30BTIG$14123.8% downsideOpen
2026-04-30Needham$13626.5% downsideOpen
2026-02-18NeedhamDavid Saxon$12731.4% downsideOpen
2026-02-18Wells Fargo$13527% downsideOpen
2026-01-28BTIG$13129.2% downsideOpen
2026-01-22Stifel Nicolaus$16013.5% downsideOpen
2026-01-14Piper Sandler$16510.8% downsideOpen
2026-01-09Goldman Sachs$13825.4% downsideOpen
2026-01-02Stephens$14521.6% downsideOpen
2025-12-23UBS$14521.6% downsideOpen
2025-12-18Truist Financial$14521.6% downsideOpen
2025-12-17UBS$16510.8% downsideOpen
2025-12-17Piper Sandler$6167% downsideOpen
2025-12-09Needham$12532.4% downsideOpen
2025-11-10UBSDanielle Antalffy$14024.3% downsideOpen
2025-10-30Truist FinancialRichard Newitter$12035.1% downsideOpen
2025-10-30BTIG$11637.3% downsideOpen
2025-10-30Wells Fargo$12234.1% downsideOpen
2025-10-30NeedhamDavid Saxon$11736.8% downsideOpen
2025-10-27Stifel NicolausThomas Stephan$11537.9% downsideOpen
2025-10-13BTIGRyan Zimmerman$10443.8% downsideOpen
2025-10-01Goldman Sachs$10344.3% downsideOpen
2025-07-31Mizuho Securities$13029.7% downsideOpen
2025-05-01Truist FinancialRichard Newitter$13527% downsideOpen
2024-12-31Stifel NicolausThomas Stephan$1755.4% downsideOpen
2024-12-18Truist FinancialRichard Newitter$1850% upsideOpen
2024-12-02Stifel NicolausThomas Stephan$15317.3% downsideOpen
2024-12-02Morgan StanleyPatrick Wood$12035.1% downsideOpen
2024-11-05NeedhamDavid Saxon$14919.5% downsideOpen
2024-11-05BTIGRyan Zimmerman$14024.3% downsideOpen
2024-10-29JefferiesMichael Sarcone$15516.2% downsideOpen
2024-10-21Truist FinancialSamuel Brodovsky$15217.9% downsideOpen
2024-10-17Piper SandlerMatt O'Brien$14024.3% downsideOpen
2024-09-23BTIGRyan Zimmerman$13924.9% downsideOpen
2024-09-03Stifel NicolausThomas Stephan$14521.6% downsideOpen
2024-06-05Stifel NicolausThomas Stephan$13029.7% downsideOpen

Glaukos (GKOS) FAQ

Glaukos's target price stands at $180. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $180 for GKOS implies 2.3% downside versus today's price ($185.04). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Glaukos's target price evolved across reporting periods, while the comparison chart places GKOS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Glaukos's reading of $180 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.